Sugi Predict

Sugi Predict / Compounds / Clostebol

Clostebol

Clostebol

SCHEMBL4437252

C[C@]12CCC(=O)C(Cl)=C1CC[C@@H]1[C@H]2CC[C@]2(C)C(O)CC[C@@H]12

nearest known ligand 0.76

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SHBG P04278 6/20 0.76
▸ SRD5A2 P31213 2/20 0.65
▸ CYP19A1 P11511 7/20 0.58
▸ CYP3A4 P08684 4/20 0.58
▸ AR P10275 4/20 0.58
▸ LMNA P02545 3/20 0.58
▸ HSD17B10 Q99714 3/20 0.58
▸ TSHR P16473 3/20 0.58
▸ NR3C1 P04150 2/20 0.58
▸ PGR P06401 2/20 0.58
▸ SERPINA6 P08185 2/20 0.58
▸ SNCA P37840 2/20 0.58
▸ CACNA1C Q13936 2/20 0.58
▸ CYP51A1 Q16850 2/20 0.58
▸ GPBAR1 Q8TDU6 2/20 0.58
▸ SIGMAR1 Q99720 2/20 0.58
▸ MAPT P10636 1/20 0.58
▸ MAPK1 P28482 1/20 0.58
▸ OR51E2 Q9H255 1/20 0.58
▸ ESR1 P03372 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Clostebol SCHEMBL146712 1.00 SHBG (0.76) SHBGSRD5A2CYP19A1CYP3A4AR
Clostebol SCHEMBL216172 0.95 SHBG (0.69) SHBGSRD5A2CYP19A1CYP3A4AR
Clostebol SCHEMBL23458227 0.92 SHBG (0.65) SHBGSRD5A2CYP19A1CYP3A4AR
Clostebol SCHEMBL23458372 0.88 SHBG (0.60) SHBGSRD5A2CYP19A1CYP3A4AR
SCHEMBL2545773 0.87 SHBG (0.79) SHBGSRD5A2CYP19A1CYP3A4AR
SCHEMBL21850133 0.87 SHBG (0.79) SHBGSRD5A2CYP19A1CYP3A4AR
SCHEMBL1682762 0.87 SHBG (0.79) SHBGSRD5A2CYP19A1CYP3A4AR
SCHEMBL22100655 0.87 SHBG (0.79) SHBGSRD5A2CYP19A1CYP3A4AR
SCHEMBL2733387 0.86 SHBG (1.00) SHBGSRD5A2CYP19A1CYP3A4AR
SCHEMBL10274070 0.86 SHBG (1.00) SHBGSRD5A2CYP19A1CYP3A4AR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210346385-A1 TASTE-MASKED DOSAGE FORMS DEEP OCEAN CAPITAL MANAGEMENT LP 2021-11-11 — — US disclosed
US-20210199646-A1 SAMPLE DEPLETION AND ENRICHMENT TO IMPROVE THE QUALITY OF DIAGNOSTIC TEST RESULTS VERAVAS, INC. 2021-07-01 — — US disclosed
US-10948484-B2 Sample depletion and enrichment to improve the quality of diagnostic test results VERAVAS, INC. (US) 2021-03-16 — — US disclosed
US-20190137484-A9 Sample depletion and enrichment to improve the quality of diagnostic test results VERAVAS, INC. (US) 2019-05-09 — — US disclosed
US-20180292394-A1 Sample depletion and enrichment to improve the quality of diagnostic test results SOLDO JOSHUA CAINE (US) 2018-10-11 — — US disclosed
US-20150152348-A1 SYSTEMS AND METHODS FOR COLLECTING, TRANSPORTING AND REPURPOSING OR DESTROYING UNUSED PHARMACEUTICALS SHARPS COMPLIANCE, INC. OF TEXAS 2015-06-04 — — US disclosed
EP-2069790-B1 BINDING SURFACES FOR AFFINITY ASSAYS BECKMAN COULTER INC (US) 2015-04-29 — — EP disclosed
US-8518714-B2 Binding surfaces for affinity assays BECKMAN COULTER, INC. (US) 2013-08-27 — — US disclosed
EP-2069790-A2 BINDING SURFACES FOR AFFINITY ASSAYS Beckman Coulter, Inc. (US) 2009-06-17 — — EP disclosed
US-20080207601-A1 Methods of and Compositions For the Prevention of Anxiety, Substance Abuse, and Dependence HYTHIAM , INC. (US) 2008-08-28 — — US disclosed
US-20080176340-A1 Binding surfaces for affinity assays BECKMAN COULTER, INC. (US) 2008-07-24 — — US disclosed
WO-2008057366-A2 BINDING SURFACES FOR AFFINITY ASSAYS BECKMAN COULTER, INC. (US) 2008-05-15 — — WO disclosed
EP-1868593-A2 IMPROVED METHODS OF AND COMPOSITIONS FOR THE PREVENTION OF ANXIETY, SUBSTANCE ABUSE, AND DEPENDENCE Hythiam, Inc. (US) 2007-12-26 — — EP disclosed
US-20070141710-A1 Stable calibrators for immunoassays BECKMAN COULTER, INC. (US) 2007-06-21 — — US disclosed
WO-2006110642-A2 IMPROVED METHODS OF AND COMPOSITIONS FOR THE PREVENTION OF ANXIETY, SUBSTANCE ABUSE, AND DEPENDENCE HYTHIAM, INC. (US) 2006-10-19 — — WO disclosed
US-20050282793-A1 Steroid prodrugs with androgenic action BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2005-12-22 — — US disclosed
US-4684728-A Solubilizing biologically active compounds with reactive hydrogen atoms BAYER AKTIENGESELLSCHAFT (DE) 1987-08-04 — — US disclosed
EP-0017772-B1 METHOD OF IMPROVING THE SOLUBILITY OF BIOLOGICALLY ACTIVE AGENTS IN WATER AND IN LOWER ALIPHATIC ALCOHOLS, AND COMPOUNDS HAVING AN IMPROVED SOLUBILITY BAYER AG (DE) 1982-07-28 — — EP disclosed
EP-0014263-B1 METHOD OF IMPROVING THE SOLUBILITY OF BIOLOGICALLY ACTIVE AGENTS IN WATER AND IN LOWER ALIPHATIC ALCOHOLS, AND COMPOUNDS HAVING AN IMPROVED SOLUBILITY BAYER AG (DE) 1982-05-05 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282793-A1 Steroid prodrugs with androgenic action CYP21A2, CYP17A1, NR5A1 SHBG 6/4885SRD5A2 8/4885CYP19A1 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.